{"id":"aplidin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition leads to an increase in histone acetylation, which in turn causes a decrease in the expression of genes involved in cell proliferation and survival. As a result, Aplidin exerts its anti-tumor effects by inducing apoptosis and cell cycle arrest in cancer cells.","oneSentence":"Aplidin is a chemotherapeutic agent that works by inhibiting the enzyme histone deacetylase (HDAC).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:44.519Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT03117361","phase":"PHASE2","title":"Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide","status":"TERMINATED","sponsor":"PharmaMar","startDate":"2017-05-08","conditions":"Multiple Myeloma","enrollment":10},{"nctId":"NCT00780975","phase":"PHASE2","title":"A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"PharmaMar","startDate":"2005-02","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT02100657","phase":"PHASE1","title":"Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2014-06","conditions":"Multiple Myeloma","enrollment":39},{"nctId":"NCT01149681","phase":"PHASE2","title":"Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2010-07","conditions":"Myelofibrosis","enrollment":12},{"nctId":"NCT00780143","phase":"PHASE1, PHASE2","title":"Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia","status":"TERMINATED","sponsor":"PharmaMar","startDate":"2007-11","conditions":"Relapsed/Refractory Leukemia","enrollment":3},{"nctId":"NCT00884286","phase":"PHASE2","title":"Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2004-12","conditions":"Leukemia, Lymphoma","enrollment":67},{"nctId":"NCT00229203","phase":"PHASE2","title":"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2005-02","conditions":"Multiple Myeloma","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["plitidepsin"],"phase":"phase_2","status":"active","brandName":"Aplidin®","genericName":"Aplidin®","companyName":"PharmaMar","companyId":"pharmamar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aplidin is a chemotherapeutic agent that works by inhibiting the enzyme histone deacetylase (HDAC). Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}